- Home
- STTK vs CNVS Comparison
STTK vs CNVS Comparison
Compare STTK & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CNVS
- Stock Information
- Founded
- STTK 2016
- CNVS 2000
- Country
- STTK United States
- CNVS United States
- Employees
- STTK N/A
- CNVS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CNVS Consumer Electronics/Video Chains
- Sector
- STTK Health Care
- CNVS Consumer Discretionary
- Exchange
- STTK Nasdaq
- CNVS Nasdaq
- Market Cap
- STTK 56.8M
- CNVS 56.2M
- IPO Year
- STTK 2020
- CNVS 2003
- Fundamental
- Price
- STTK $1.11
- CNVS $3.54
- Analyst Decision
- STTK Hold
- CNVS Buy
- Analyst Count
- STTK 3
- CNVS 1
- Target Price
- STTK $2.00
- CNVS $10.00
- AVG Volume (30 Days)
- STTK 172.1K
- CNVS 104.5K
- Earning Date
- STTK 02-27-2025
- CNVS 02-12-2025
- Dividend Yield
- STTK N/A
- CNVS N/A
- EPS Growth
- STTK N/A
- CNVS N/A
- EPS
- STTK N/A
- CNVS N/A
- Revenue
- STTK $6,435,000.00
- CNVS $45,005,000.00
- Revenue This Year
- STTK $313.04
- CNVS $50.96
- Revenue Next Year
- STTK N/A
- CNVS N/A
- P/E Ratio
- STTK N/A
- CNVS N/A
- Revenue Growth
- STTK 382.75
- CNVS N/A
- 52 Week Low
- STTK $0.94
- CNVS $0.72
- 52 Week High
- STTK $11.76
- CNVS $4.19
- Technical
- Relative Strength Index (RSI)
- STTK 44.36
- CNVS 49.00
- Support Level
- STTK $1.13
- CNVS $3.34
- Resistance Level
- STTK $1.22
- CNVS $3.60
- Average True Range (ATR)
- STTK 0.11
- CNVS 0.23
- MACD
- STTK -0.01
- CNVS -0.05
- Stochastic Oscillator
- STTK 15.15
- CNVS 28.57
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About CNVS Cineverse Corp.
Cineverse Corp is a main streaming technology and entertainment company. It operates portfolios of owned and operated streaming channels, all powered by its, proprietary technology platform. Cineverse features enthusiast brands for subscription video on demand (SVOD), advertising-based video on demand (AVOD), and free, ad-supported streaming television (FAST) channels. The company earns fees for the distribution of content in the home entertainment markets via several distribution channels, including digital, video-on-demand, and physical goods (e.g., DVDs and Blu-ray Discs) (Base Distribution).